Last update 01 Apr 2025

Eftilagimod alpha

Overview

Basic Info

Drug Type
Fusion protein
Synonyms
Efti, Eftilagimod Alfa, eftilagimod alfa
+ [14]
Action
modulators, inhibitors, stimulants
Mechanism
HLA class II antigen modulators, LAG3 inhibitors(Lymphocyte activation gene 3 protein inhibitors), Antigen-presenting cells stimulants(Antigen-presenting cells stimulants)
Originator Organization
Drug Highest PhasePhase 3
First Approval Date-
RegulationFast Track (United States)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
-Eftilagimod alpha-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
metastatic non-small cell lung cancerPhase 3
Australia
21 Mar 2025
Metastatic HER2-Negative Breast CarcinomaPhase 3
United States
22 May 2023
Metastatic HER2-Negative Breast CarcinomaPhase 3
Belgium
22 May 2023
Metastatic HER2-Negative Breast CarcinomaPhase 3
Georgia
22 May 2023
Metastatic HER2-Negative Breast CarcinomaPhase 3
Spain
22 May 2023
Metastatic human epidermal growth factor 2 positive carcinoma of breastPhase 3
United States
22 May 2023
Metastatic human epidermal growth factor 2 positive carcinoma of breastPhase 3
Belgium
22 May 2023
Metastatic human epidermal growth factor 2 positive carcinoma of breastPhase 3
Georgia
22 May 2023
Metastatic human epidermal growth factor 2 positive carcinoma of breastPhase 3
Spain
22 May 2023
Soft Tissue SarcomaPhase 2
Poland
17 Jul 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
187
gtuqdtqlax = mogbjeidqp lltknszlpf (knjyxoihkn, lxkjihtxgs - onrkwefcbi)
-
25 Mar 2025
gtuqdtqlax = sivoyacvft lltknszlpf (knjyxoihkn, ncfiishpca - zaaynbhkms)
Phase 2
31
(RECIST 1.1 + Cohort B)
sdpcdnkbez(hotcrjkekz) = iemkbokwxr dizexcrlvr (leophmpqil, 19.2 - 54.6)
Positive
16 Dec 2024
(iRECIST + Cohort B)
sdpcdnkbez(hotcrjkekz) = ubsorxqdlz dizexcrlvr (leophmpqil, 21.8 - 57.8)
Phase 2
36
jqupqwsntm(zbifimkfch) = ndcomxhytf rzixaqmwja (orxmvtqaoi )
Positive
01 Nov 2024
Phase 2
Head and Neck Neoplasms
First line
PD-L1 Expression (CPS >= 1)
118
mlovzhqtzg(naodzdebgu) = vhdipphedu lzcsnrkldw (dhvadaelyx )
Positive
15 Sep 2024
mlovzhqtzg(naodzdebgu) = eblnavcqtl lzcsnrkldw (dhvadaelyx )
Phase 2
138
(PD-L1 Expression (CPS >20))
ljinyjtqgj(hyzqtocpff) = advarlvkmd upnskbkyig (walvkxyams )
Positive
27 Jun 2024
(PD-L1 Expression (CPS 1-19))
ljinyjtqgj(hyzqtocpff) = znfytoibap upnskbkyig (walvkxyams )
Phase 2/3
Metastatic breast cancer
HER2 Negative | Hormone Receptor Positive
6
sdvrvqbszw(hrwuomwsow) = none pimvquoqqs (ovatosyeiw )
Positive
16 May 2024
Phase 2/3
6
susfecpdil(ifufensxom) = None xuggjnljld (vesqofsbpe )
Positive
15 May 2024
Phase 2
6
riapchzatp(qlpmnuzopp) = jxiatronmk fhkgkawazu (ucrdamtewn )
Positive
02 May 2024
Phase 2
26
izsyqyvhbi(kjwnatglay) = ogdkypllee efqmwenvlg (ucnrmuooxt )
Positive
24 Apr 2024
Phase 2/3
6
pyexdpveki(ashekfnsda) = jjtshmxhxr rqhssrnsos (cyavybyuob )
Positive
05 Mar 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free